Keith Meister Sells 283,269 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 283,269 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total transaction of $56,543,325.09. Following the sale, the director owned 2,089,425 shares in the company, valued at approximately $417,070,124.25. This trade represents a 11.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Illumina Stock Down 3.0%

Shares of NASDAQ:ILMN opened at $187.96 on Friday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The firm has a fifty day moving average of $181.13 and a 200 day moving average of $149.05. The firm has a market capitalization of $28.38 billion, a PE ratio of 35.07, a price-to-earnings-growth ratio of 2.73 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the business posted $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Illumina

A number of large investors have recently bought and sold shares of ILMN. Elyxium Wealth LLC purchased a new position in shares of Illumina in the fourth quarter worth $25,000. Creative Capital Management Investments LLC boosted its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new stake in Illumina in the 4th quarter worth $26,000. Laurel Wealth Advisors LLC bought a new stake in Illumina in the 4th quarter worth $26,000. Finally, Activest Wealth Management increased its position in shares of Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent research reports. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Canaccord Genuity Group increased their target price on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday. Finally, Citigroup lifted their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $188.40.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Zacks upgraded Illumina to Rank #1, or “Strong Buy,” citing improving earnings prospects and strong momentum characteristics. The upgrade could attract near-term buying interest. What Makes Illumina a New Strong Buy Stock
• Positive Sentiment: Illumina’s latest quarterly results provide a supportive backdrop: earnings per share exceeded estimates, revenue topped forecasts, and sales increased 9.4% year over year. The company continues to guide to fiscal 2026 EPS of $5.30 to $5.40. Recent bullish analysts have raised price targets as high as $230. Illumina Earnings and Analyst Information
• Neutral Sentiment: Analyst opinion remains divided. Although several firms maintain Buy or Outperform ratings, the consensus rating is “Hold,” with an average price target of $188.40—close to recent trading levels—suggesting limited consensus upside.
• Negative Sentiment: Director Keith A. Meister sold 741,127 shares across August 4 and 5 for approximately $148.2 million, reducing his position by about 28%. He retains more than 2 million shares, but the size of the transactions may pressure sentiment and raise concerns about insider confidence. Illumina Insider Trading Filing
• Negative Sentiment: Bank of America Securities reiterated its “Sell” rating and $140 price target, arguing that a one-time consumables benefit may be masking weak underlying demand. The target is well below recent levels, highlighting valuation and sustainability concerns. Bank of America Maintains Sell Rating

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.